Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin ( <scp>IL</scp> )‐17 or <scp>IL</scp> ‐12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review-Reference-Cited by-同舟云学术

Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin ( IL )‐17 or IL ‐12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review

Published:2022-06-25 Issue:9 Volume:47 Page:1627-1635
ISSN:0307-6938
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:Clin Experimental Derm

Author:

Xie Yan¹^ORCID,Liu Yang²

Affiliation:

1. Department of Rheumatology and Immunology West China Hospital, Sichuan University Chengdu China

2. Tsinghua Clinical Research Institute (TCRI), School of Medicine Tsinghua University Beijing China

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ced.15237

Reference25 articles.

1. Psoriasis

2. Psoriatic Arthritis

3. Psoriasis and psoriatic arthritis treatment;Menter A;Am J Manag Care,2016

4. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update

5. Management of psoriasis as a systemic disease: what is the evidence?

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target;Expert Opinion on Biological Therapy;2024-09-08

2. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL;RMD Open;2024-02

3. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE);The Lancet;2023-01